BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 28, 2009
 |  BC Week In Review  |  Company News  |  Deals

Bio-Path, M.D. Anderson Cancer Center deal

Bio-Path received exclusive, worldwide rights to develop the center's liposome tumor targeting technology for neutral lipid-based liposome delivery of antisense and focal adhesion kinase (FAK) siRNA to tumor tissue....

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >